Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

For Industry

  • Print
  • Share
  • E-mail
-

Standard Costs (in thousands of dollars) for Components of the Process for the Review of Human Drug Applications

Revised to Incorporate FY 2011 Standard Costs

Previous years (FY 1993 - FY 2002) 

 

Accessible text                                                          FY 2003 - FY 2011

Estimates Made Pursuant to Section 736(d)(2) of the Federal Food, Drug, and Cosmetic Act  
 From Time Rpt.  
Submission TypeFY 03FY 04FY 05FY 06FY 07FY 08FY 09FY 10FY 11
Drug Applications     
IND$299$203.3$240$249.6$284.7$236.5$290.9$362.1$423.3
NDA with Clinical Data - NME$2,116$1,987.1$2,456.3$2,986.2$2,250.9$3,736.4$4,021.0$4,316.6$5,091.6
NDA with Clinical Data - Non-NME$746$760.1$684.6$777.1$804.9$1,320.9$1,313.1$1,863.6$2,368.5
NDA without Clinical Data$561$411.5$476.5$481$239.6$288.7$398.4$502.1$917.1
Supplement with Clinical Data$175$142.2$255.4$224.4$247.8$364.0$555.9$615.7$693.7
Supplement without Clinical Data$18$16.7$16.5$22.7$19.4$13.8$28.7$31.4$17.8
Biologic Applications  
IND$361$400.4$437.1$393.9$427.5$802.8$860.4$791.9$1,000.8
BLA$4,394$4,074.7$4,492.2$2,626.2$3,141.6$2,726.7$3,529.6$6,081.5$11,203.5
PLA         
ELA         
Supplement with Clinical Data$228$367.4$239.4$265.2$627.1$511.5$681.8$655.4$661.3
Supplement without Clinical Data$21$41$41.9$40.2$53$49.4$68.3$72.8$83.8
1 Standard costs include all costs associated with application review, including rent, overhead, and centrally funded costs. Method revised in FY 2001-2002 based on KPMG study, and in 2003 on time reporting data. Time reporting method revised with better allocation of indirect cost beginning in 2004.

                                                           

Accessible text                                                     FY 1993 - FY 2002

Estimates Made Pursuant to Section 736(d)(2)of the Federal Food, Drug, and Cosmetic Act
 All determined on the basis of the Arthur Andersen model developed in 1993KPMG Model
Submission TypeFY 93FY 94FY 95FY 96FY 97FY 98FY 99FY 00FY 01FY 02
Drug Applications
IND$70$79$98$97$84$94$105$119$200$211.8
NDA with Clinical Data - NME$887$1,004$1,243$1,233$1,065$1,194$1,328$1,503$1,920$2,037.0
NDA with Clinical Data - Non-NME$298$337$417$414$358$401$446$505$929$985.9
NDA without Clinical Data$127$144$178$177$152$171$190$215$261$276.6
Supplement with Clinical Data$151$171$212$210$181$203$226$256$111$118.1
Supplement without Clinical Data$6$7$8$8$7$8$9$10$8$8.1
Biologic Applications
IND$184$230$234$266$204$173$243$175$287$278.9
BLA     $1,118$1,568$1,128$2,788$2,708.2
PLA$1,078$1,345$1,369$1,560$1,194$1,016$1,426$1,026  
ELA$177$221$225$256$196$167$234$168  
Supplement with Clinical Data$561$700$713$812$622$529$742$534$195$189.6
Supplement without Clinical Data$34$42$43$49$38$32$45$32$31$29.8
1 Standard costs include all costs associated with application review, including rent, overhead, and centrally funded costs. Method revised in FY 2001-2002 based on KPMG study, and in 2003 on time reporting data. Time reporting method revised with better allocation of indirect cost beginning in 2004.

 

 Back to PDUFA Guidance Documents

 

-
-